DOI QR코드

DOI QR Code

Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging

  • Zhang, Feng-Lin (Department of Oncology, Maanshan City People's Hospital) ;
  • Gao, Er-Yun (Department of Oncology, Maanshan City People's Hospital) ;
  • Shu, Rong-Bao (Department of Oncology, Maanshan City People's Hospital) ;
  • Wang, Hui (Department of Oncology, Maanshan City People's Hospital) ;
  • Zhang, Yan (Department of Oncology, Maanshan City People's Hospital) ;
  • Sun, Peng (Department of Oncology, Maanshan City People's Hospital) ;
  • Li, Min (Department of Oncology, Maanshan City People's Hospital) ;
  • Tang, Wei (Department of Oncology, Maanshan City People's Hospital) ;
  • Jiang, Bang-Qin (Department of Oncology, Maanshan City People's Hospital) ;
  • Chen, Shuang-Qi (Department of Oncology, Maanshan City People's Hospital) ;
  • Cui, Fang-Bo (Department of Oncology, Maanshan City People's Hospital)
  • Published : 2015.10.06

Abstract

Aims: To study the effectiveness of human recombinant endostatin injection (Endostar(R)) combined with cisplatin doublets in treating advanced non-small cell lung cancer (NSCLC), and to evaluate outcome by CT perfusion imaging. Methods: From April 2011 to September 2014, 76 patients with advanced NSCLC who were treated with platinum-based doublets were divided into group A (36 patients) and group B (40 patients). Endostar(R) 15mg/day was administered 4 days before chemotherapy and combined with chemotherapy from day 5 in group A, and combined with chemotherapy from the first day in Group B. Endostar(R) in the two groups was injected intravenously for 14 days. Results: Treatment effectiveness in the two groups differed with statistical significance (p<0.05). Effectiveness evaluated by CT perfusion imaging, BF, BV, MTT and PS also demonstrated significant differences (all p<0.05). Adverse reactions in the two groups did not significantly vary (p> 0.05). Conclusions: The response rate with Endostar(R) administered 4 days before chemotherapy and combined with chemotherapy from day 5 in group A was better than Endostar(R) combined with chemotherapy from the first day, and CT perfusion imaging could be a reasonable method for evaluation of patient outcomes.

Keywords

Advanced NSCLC;platinum containing chemotherapy;CT perfusion imaging

Acknowledgement

Supported by : National Natural Science Foundation of China

References

  1. Bowles DW, Weickhardt AJ, Doebele RC, et al (2012). Crizotinib for the treatment of patients with advanced non-small cell lung cancer. Drugs Today (Barc), 48, 271-82. https://doi.org/10.1358/dot.2012.48.4.1769835
  2. Cui L, Liu XX, Jiang Y, et al (2014). Phase II study on dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 1699-702. https://doi.org/10.7314/APJCP.2014.15.4.1699
  3. Dai YM, Cui TJ, Liu ZH et al (2012). Human recombinant endostatin combined with cisplatin based chemotherapy in treating patients with NSCLC. J Clin Oncol, 17, 1036-9.
  4. Fei ZH, Yao CY, Yang XL,et al (2013). Serum BMP-2 upregulation as an indicator of poor survival in advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev, 14, 5293-9. https://doi.org/10.7314/APJCP.2013.14.9.5293
  5. Fukuoka M, Wu YL, Thongprasert S, et al (2011). Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol, 29, 2866-74. https://doi.org/10.1200/JCO.2010.33.4235
  6. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med, 359, 1367-80. https://doi.org/10.1056/NEJMra0802714
  7. Huang XE, Tian GY, Cao J, et al (2014). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7.
  8. Huang XE, Cao J, Qian ZY, et al (2014). Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia. Asian Pac J Cancer Prev, 15, 8495-7. https://doi.org/10.7314/APJCP.2014.15.19.8495
  9. Ji ZQ, Huang XE, Wu XY, et al (2014). Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev, 15, 8603-5. https://doi.org/10.7314/APJCP.2014.15.20.8603
  10. Tian Y, Tang Z, We K, et al (2012). Meta analysis on Human recombinant endostatin combined with cisplatin based chemotherapy in treating patients with NSCLC. Chongqing Medical J, 37, 151-7.
  11. Welsh JW, Komaki R, Amini A, et a1 (2013). Phase 2 trial of erlotinib plus concurrent whole brain radiation therapy for patients with brain metastases from non-small-cell lung caneer. J Clin Oncol, 31, 895-902. https://doi.org/10.1200/JCO.2011.40.1174
  12. Wen L, Wang YS, Zhang CY et al(2013). Human recombinant endostatin administered in different time for SPC-A1. Chin Drug Clinic, 13, 21-2.
  13. Zhang Y, Liu PS (2013). Human recombinant endostatin combined with chemotherapy in treating 129 patients with NSCLC. Chin Social Physician, 15, 181-2.

Cited by

  1. Expression of Inhibitor of Differentiation-1 and Its Effects on Angiogenesis in Gastric Cancer vol.31, pp.7, 2016, https://doi.org/10.1089/cbr.2016.2043
  2. Assessing Tumor Response to Treatment in Patients with Lung Cancer Using Dynamic Contrast-Enhanced CT vol.6, pp.3, 2016, https://doi.org/10.3390/diagnostics6030028